RIPK1 and neoplasm: Recent studies have demonstrated that the inhibition of RIPK1 kinase activity enhances antitumor immunity by modulating tumour-associated macrophages (TAMs), indicating that RIPK1 may serve as a promising immunomodulatory target for the development of innovative anticancer therapies.102